TUESDAY, Jan. 18, 2022 (HealthDay News) -- Presence of an appendicolith is associated with a nearly twofold increased risk for undergoing appendectomy within 30 days of initiating antibiotics for appendicitis, according to a study published online Jan. 12 in JAMA Surgery.
Search / 212 results found Showing: 1-10 of 212
TUESDAY, Jan. 18, 2022 (HealthDay News) -- Before getting their first dose of a COVID vaccine, many Americans were nervous about how they would react to the shot, but new research shows that fears of side effects may actually make side effects more likely.
TUESDAY, Jan. 18, 2022 (American Heart Association News) -- Two years into the pandemic, researchers have learned a lot about how COVID-19 affects people with heart disease and stroke survivors. But like the coronavirus itself, what everyone needs to know keeps evolving.
HOUSTON, Jan. 18, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported that it has received an updated independent safety review of certain preliminary data for the first 30 patients in its three Phase 1 clinical trials with Annamycin targeting relapsed or refractory acute myeloid leukemia (AML) and the metastases of soft tissue sarcoma to the lungs (STS Lung), which concluded there was no evidence of cardiotoxicity. The review included analysis of ejection fraction, echo strain and certain troponin levels intended to assess potential for both acute and chronic heart damage. Additionally, the Company reported evidence that Annamycin may have a substantially lower incidence of alopecia (hair loss) than currently prescribed anthracyclines such as doxorubicin. Although 65%-92% of patients treated with doxorubicin typically experience hair loss, the incidence to date in patients treated with Annamycin is less than 10%. Alopecia is considered an important factor in quality of life for many cancer patients.
DALLAS, Jan. 18, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a collaboration and research agreement with The Danish Cancer Society Research Center (DCRC) to support clinical development of Lantern's acylfulvene class drug candidates, LP-100 and LP-184, as well as the development of improved diagnostic methods to identify nucleotide excision repair (NER) deficient tumors. LP-100 and LP-184 have both shown synthetically lethal impact in tumors that are lacking NER capabilities. The DCRC is a cancer research institute within the Danish Cancer Society. The Danish Cancer Society is Denmark's largest non-government organization and dedicates more than 60% of its budget to research, with the remainder shared between prevention and patient support initiatives. Lantern expects the data, genomic signatures and biological models generated from this collaboration to add millions of data points to RADR® and help accelerate the development of new indications for LP-100 and LP-184. This collaboration, together with the growing power of the RADR® platform, can potentially uncover new drug combinations using LP-100 and LP-184 for cancer treatments at a fraction of the cost of traditional drug development.
MONDAY, Jan. 17, 2022 (HealthDay News) -- U.S. insurers are paying millions of dollars a year to cover the cost of ivermectin for COVID-19 patients despite a lack of proof the anti-parasitic drug is effective against the virus, a new study finds.
This week, the U.S. Food and Drug Administration approved a new treatment for osteoarthritis in cats, marking the first time a monoclonal antibody drug has been FDA approved for treatment of animal diseases.
Here is what the editors at Physician's Briefing chose as the most important COVID-19 developments for you and your practice for the week of Jan. 10 to 14, 2022. This roundup includes the latest research news from journal studies and other trusted sources that is most likely to affect clinical practice.